A2 Vertaisarvioitu katsausartikkeli tieteellisessä lehdessä
How to Optimize Cardioversion of Atrial Fibrillation
Tekijät: Airaksinen KE Juhani
Kustantaja: MDPI
Julkaisuvuosi: 2022
Journal: Journal of Clinical Medicine
Tietokannassa oleva lehden nimi: JOURNAL OF CLINICAL MEDICINE
Lehden akronyymi: J CLIN MED
Artikkelin numero: 3372
Vuosikerta: 11
Numero: 12
Sivujen määrä: 7
eISSN: 2077-0383
DOI: https://doi.org/10.3390/jcm11123372
Verkko-osoite: https://doi.org/10.3390/jcm11123372
Rinnakkaistallenteen osoite: https://research.utu.fi/converis/portal/detail/Publication/175886892
Tiivistelmä
Cardioversion (CV) is an essential component of rhythm control strategy in the treatment of atrial fibrillation (AF). Timing of CV is an important manageable factor in optimizing the safety and efficacy of CV. Based on observational studies, the success rate of CV seems to be best (approximate to 95%) at 12-48 h after the onset of arrhythmic symptoms compared with a lower success rate of approximate to 85% in later elective CV. Early AF recurrences are also less common after acute CV compared with later elective CV. CV causes a temporary increase in the risk of thromboembolic complications. Effective anticoagulation reduces this risk, especially during the first 2 weeks after successful CV. However, even during therapeutic anticoagulation, each elective CV increases the risk of stroke 4-fold (0.4% vs. 0.1%) during the first month after the procedure, compared with acute (<48 h) CV or avoiding CV. Spontaneous CVs are common during the early hours of AF. The short wait-and-see approach, up to 24-48 h, is a reasonable option for otherwise healthy but mildly symptomatic patients who are using therapeutic anticoagulation, since they are most likely to have spontaneous rhythm conversion and have no need for active CV. The probability of early treatment failure and antiarrhythmic treatment options should be evaluated before proceeding to CV to avoid the risks of futile CVs.
Cardioversion (CV) is an essential component of rhythm control strategy in the treatment of atrial fibrillation (AF). Timing of CV is an important manageable factor in optimizing the safety and efficacy of CV. Based on observational studies, the success rate of CV seems to be best (approximate to 95%) at 12-48 h after the onset of arrhythmic symptoms compared with a lower success rate of approximate to 85% in later elective CV. Early AF recurrences are also less common after acute CV compared with later elective CV. CV causes a temporary increase in the risk of thromboembolic complications. Effective anticoagulation reduces this risk, especially during the first 2 weeks after successful CV. However, even during therapeutic anticoagulation, each elective CV increases the risk of stroke 4-fold (0.4% vs. 0.1%) during the first month after the procedure, compared with acute (<48 h) CV or avoiding CV. Spontaneous CVs are common during the early hours of AF. The short wait-and-see approach, up to 24-48 h, is a reasonable option for otherwise healthy but mildly symptomatic patients who are using therapeutic anticoagulation, since they are most likely to have spontaneous rhythm conversion and have no need for active CV. The probability of early treatment failure and antiarrhythmic treatment options should be evaluated before proceeding to CV to avoid the risks of futile CVs.
Ladattava julkaisu This is an electronic reprint of the original article. |  |
Turun yliopiston Tutkimustietojärjestelmän portaali